Advanced search

Instruments

Name		Stock exchange	Average volume	Price	Type
ALTSHULER SHAHAM FINANCE LTD	ALTF	TEL AVIV STOCK EXCHANGE	1,176,550	460.2 ILa	Stock
ALBERT DAVID LIMITED	ALBERTDAVD	Bombay S.E. +1 Other	1,609	1,180 INR	Stock
ALBERT DAVID LIMITED	ALBERTDAVD	NSE India S.E.	10,449	1,181 INR
NINGBO DAVID MEDICAL DEVICE CO., LTD.	300314	Shenzhen S.E.	11,195,721	12 CNY	Stock
ENDLOS INDEXZERTIFIKAT - LUS WIKIFOLIO-INDEX DAVID GEGEN GOLIATH - NUR AKTIEN	LS9LPV	Berne S.E.	-	- CHF	Certificat
ENDLOS INDEXZERTIFIKAT - LUS WIKIFOLIO-INDEX DAVID GEGEN GOLIATH - NUR AKTIEN		Börse Stuttgart	-	186.9 EUR	Certificat

News (92)

Vertex Pharma scientist talks about the long road to developing non-addictive painkillers	16/04	AQ
Transcript : Vertex Pharmaceuticals Incorporated Presents at Leerink Partners Global Biopharma Conference 2024, Mar-11-2024 04:00 PM	12/03
Transcript : Vertex Pharmaceuticals Incorporated Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-05-2024 10:30 AM	05/03
Vertex to Participate in Upcoming Investor Conferences	21/02	BU
Vertex secures European approval for CRISPR cell therapy	13/02	AQ
Transcript : Vertex Pharmaceuticals Incorporated Presents at 14th Annual Jefferies London Healthcare Conference 2023, Nov-14-2023 08:30 AM	14/11
Transcript : Vertex Pharmaceuticals Incorporated Presents at UBS Biopharma Conference 2023, Nov-09-2023 12:00 PM	09/11
Transcript : CRISPR Therapeutics AG - Special Call	31/23/31
Vertex to Present at Upcoming Investor Conferences	26/23/26	BU
Vertex Researchers Awarded 2024 Breakthrough Prize in Life Sciences	14/23/14	BU
Transcript : Vertex Pharmaceuticals Incorporated Presents at Bank of America Securities 2023 Healthcare Conference, May-09-2023 09:20 AM	09/23/09
Transcript : Vertex Pharmaceuticals Incorporated, Q4 2022 Earnings Call, Feb 07, 2023	08/23/08
Arbor Biotechnologies Announces Expanded Strategic Partnership with Vertex Now Extending to Precision Gene Editing Using Reverse Transcriptase	12/23/12	AQ
Transcript : Vertex Pharmaceuticals Incorporated Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-09-2023 08:15 AM	09/23/09
Vertex and Entrada Therapeutics Establish Collaboration to Discover and Develop Endosomal Escape Vehicle Therapeutics for Myotonic Dystrophy Type 1	09/22/09	AQ
Vertex and Entrada Therapeutics Establish Collaboration to Discover and Develop Endosomal Escape Vehicle (EEV) Therapeutics for Myotonic Dystrophy Type 1 (DM1)	08/22/08	BU
Vertex Advances Program Targeting Alpha-1 Antitrypsin Deficiency	11/22/11	BU
Vertex and Verve Therapeutics Establish Collaboration to Discover and Develop an In Vivo Gene Editing Program for Liver Disease	21/22/21	GL
Vertex and Verve Therapeutics Establish Collaboration to Discover and Develop an In Vivo Gene Editing Program for Liver Disease	21/22/21	AQ
Transcript : Vertex Pharmaceuticals Incorporated, Q1 2022 Earnings Call, May 05, 2022	06/22/06
Transcript : Vertex Pharmaceuticals Incorporated Presents at 42nd Annual Cowen Health Care Conference, Mar-08-2022 02:50 PM	09/22/09
Transcript : Vertex Pharmaceuticals Incorporated - Special Call	01/21/01
Finnovate Acquisition Corp. Announces Closing of $22,500,000 Over-Allotment Option in Connection with its Initial Public Offering	13/21/13	AQ
Finnovate Acquisition Corp. Announces Pricing of $150,000,000 Initial Public Offering	04/21/04	AQ
Vertex and Mammoth Biosciences Announce Collaboration to Develop In Vivo Gene-Editing Therapies for Serious Diseases	26/21/26	BU
Fathom : 5 Time Management Tips for Real Estate Agents	21/21/21	PU
Transcript : Vertex Pharmaceuticals Incorporated - Special Call	11/21/11
Vertex Pharmaceuticals : and Obsidian Therapeutics Establish Collaboration to Discover Novel Therapies That Regulate Gene Editing	22/21/22	BU
Valdy Investments Ltd. Enters into Definitive Agreement for Proposed Qualifying Transaction with INX Limited	31/21/31	NE
Transcript : Vertex Pharmaceuticals Incorporated, Q4 2020 Earnings Call, Feb 01, 2021	02/21/02
CRISPR Therapeutics : Phase 1/2 CTX001™ Investor Update Presentation	09/20/09	PU
Transcript : Vertex Pharmaceuticals Incorporated, CRISPR Therapeutics AG - Special Call	09/20/09
Transcript : Vertex Pharmaceuticals Incorporated, Q3 2020 Earnings Call, Oct 29, 2020	30/20/30
Moderna : and Vertex Establish New Collaboration to Treat Cystic Fibrosis Using Gene Editing	17/20/17	AQ
Vertex Pharmaceuticals : Moderna and Vertex Establish New Collaboration to Treat Cystic Fibrosis Using Gene Editing	17/20/17	BU
Marcus & Millichap : Northern California Multifamily Online Conference	16/20/16	PU
Vertex Pharmaceuticals : FDA Accepts Vertex's Supplemental New Drug Applications for TRIKAFTA, SYMDEKO and KALYDECO for Additional CFTR Mutations	02/20/02	AQ
Vertex Pharmaceuticals : FDA Accepts Vertex’s Supplemental New Drug Applications for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) and KALYDECO® (ivacaftor) for Additional CFTR Mutations	01/20/01	BU
Transcript : Vertex Pharmaceuticals Incorporated Presents at 38th Annual J.P Morgan Healthcare Conference, Jan-13-2020 11:30 AM	14/20/14
Vertex and Molecular Templates Establish Collaboration to Discover and Develop Novel Targeted Conditioning Regimens to Enhance Hematopoietic Stem Cell Transplants	18/19/18	GL
Transcript : Vertex Pharmaceuticals Incorporated, Q3 2019 Earnings Call, Oct 30, 2019	31/19/31
Vertex Pharmaceuticals : to Acquire Semma Therapeutics With a Goal of Developing Curative Cell-Based Treatments for Type 1 Diabetes	03/19/03	BU
Transcript : Vertex Pharmaceuticals Incorporated, Q1 2019 Earnings Call, Apr 30, 2019	01/19/01
Hancock Jaffe Laboratories : General form of registration statement for all companies including face-amount certificate companies	29/19/29	PU
CRISPR Therapeutics and Vertex Announce Progress in Clinical Development Programs for the Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001	25/19/25	GL

123NextSee all

Companies (32)

ALTSHULER SHAHAM FINANCE LTD 246 M $

Altshuler Shaham Financial Ltd is an Israel-based company. Altshuler Shaham Financial Ltd is principally engaged in financial industry. The main area of the Company's operations is managing long-term savings and pension funds. It operates through its subs ...

DAVIDE CAMPARI-MILANO N.V. 13 082 M $

Davide Campari-Milano N.V. is one of the Italian's leading producers and distributors of spirits and wines. The activity is organized around three product families: - spirits: rhums, vodkas, tequilas, whiskies, liqueurs, etc. (Campari, SKYY Vodka, Cynar, ...

DAVIDE CAMPARI-MILANO N.V. 13 082 M $

BARRATT DEVELOPMENTS PLC 6 379 M $

Barratt Developments PLC is one of the leading British builders of single-family homes. The group also develops and manages real estate properties. Net sales break down by activity as follows: - construction and sales of houses (98.4%): 17,206 houses bui ...

BARRATT DEVELOPMENTS PLC 6 379 M $

MAGGIE BEER HOLDINGS LIMITED 17 M $

Maggie Beer Holdings Ltd is engaged in sale of branded premium food and beverage and gifting products in Australia and overseas markets. Its segments Maggie Beer Products Pty Ltd (MBP), Hampers & Gifts Australia Pty Ltd (HGA), and B.-d Farm Paris Creek Pt ...

DAN HOTELS LTD 586 M $

Dan Hotels Ltd is an Israel-based hotel chain which owns and operates 14 hotels throughout Israel, with a total of 3,874 rooms.The majority of the Dan Hotels are graded by the Ministry of Tourism as First Class hotels, the remainder as Tourist Class hotel ...

ALBA MINERAL RESOURCES PLC 7 M $

Alba Mineral Resources plc is engaged in the exploration and development of natural resources. The Company's mineral exploration portfolio is comprised of gold and, graphite, ilmenite, base metal and iron ore projects in a cluster of countries in northern ...

PRIME STRATEGY CO., LTD. 31 M $

Prime Strategy Co Ltd is a Japan-based company mainly engaged in the KUSANAGI Stack business. The KUSANAGI Stack Business segment consists of three main services: KUSANAGI Managed Services, Cloud Integration Services, and License Sales. The Company is als ...

RATIO ENERGIES - LIMITED PARTNERSHIP 846 M $

Ratio Energies LP,formerly known as Ratio Oil Exploration 1992 LP is an Israel-based company. The Company holds two plots in which it is actively exploring for gas and petroleum. In addition, the Company has a partnership in a few exploration fields: Mad ...

1234Next

Insiders

David R. Altshuler

Mr. David R.
Altshuler is Secretary & Director at The Digital Development Group Corp.
He is on the Board of Directors at The Digital Development Group Corp.
He received his undergraduate degree from the University of California, Irvine, a graduate degree from California Western School of Law and a graduate degree from New York University School of Law.

David Altshuler

David Altshuler currently works at M D Trading (Pty) Ltd., as Director.

David Altshuler

David Altshuler is currently a Partner & Co-Head Client Solutions at Quantum Capital Group LLC since 2023.
He was previously a Principal at Nuveen Investments, Inc. from 2001 to 2008, a Senior Vice President at Meketa Investment Group, Inc. from 2008 to 2013, and a Partner at StepStone Group LP from 2013 to 2017.
Altshuler received his undergraduate degree from The Reed Institute and his graduate and doctorate degrees from The University of Chicago.

David Altshuler

David Altshuler currently works as a trustee for the Huntington Theatre Co.

David Altshuler

Presently, David Matthew Altshuler occupies the position of Chief Scientific Officer & EVP-Global Research at Vertex Pharmaceuticals, Inc. Dr. Altshuler is also Founding Member at Whitehead Institute for Biomedical Research, Member of American Academy of Arts & Sciences, Member of Institute of Medicine, Member of Association of American Physicians, Member of American Society for Clinical Investigation and Member of National Academy of Medicine of United States and on the board of 6 other companies. In the past Dr. Altshuler held the position of Deputy Director, Chief Academic Officer & Member at The Broad Institute, Inc., Advisory Board Member at MPM Capital Inc, Professor at The General Hospital Corp., Senior Analyst at Nuveen Fund Advisors LLC, Professor at Massachusetts Institute of Technology, Director at American Society of Human Genetics, Principal at The SNP Consortium Ltd. and Professor at Harvard Medical School. David Matthew Altshuler received an undergraduate degree from Massachusetts Institute of Technology, a doctorate from Harvard University and a doctorate from Harvard Medical School.

No results for this search